205 related articles for article (PubMed ID: 29174389)
21. Effect of atorvastatin, cholesterol ester transfer protein inhibition, and diabetes mellitus on circulating proprotein subtilisin kexin type 9 and lipoprotein(a) levels in patients at high cardiovascular risk.
Arsenault BJ; Petrides F; Tabet F; Bao W; Hovingh GK; Boekholdt SM; Ramin-Mangata S; Meilhac O; DeMicco D; Rye KA; Waters DD; Kastelein JJP; Barter P; Lambert G
J Clin Lipidol; 2018; 12(1):130-136. PubMed ID: 29103916
[TBL] [Abstract][Full Text] [Related]
22. Effects of androgenic-anabolic steroids on apolipoproteins and lipoprotein (a).
Hartgens F; Rietjens G; Keizer HA; Kuipers H; Wolffenbuttel BH
Br J Sports Med; 2004 Jun; 38(3):253-9. PubMed ID: 15155420
[TBL] [Abstract][Full Text] [Related]
23. Relationship of lipoprotein(a) molar concentrations and mass according to lipoprotein(a) thresholds and apolipoprotein(a) isoform size.
Tsimikas S; Fazio S; Viney NJ; Xia S; Witztum JL; Marcovina SM
J Clin Lipidol; 2018; 12(5):1313-1323. PubMed ID: 30100157
[TBL] [Abstract][Full Text] [Related]
24. L-Carnitine/Simvastatin Reduces Lipoprotein (a) Levels Compared with Simvastatin Monotherapy: A Randomized Double-Blind Placebo-Controlled Study.
Florentin M; Elisaf MS; Rizos CV; Nikolaou V; Bilianou E; Pitsavos C; Liberopoulos EN
Lipids; 2017 Jan; 52(1):1-9. PubMed ID: 27914033
[TBL] [Abstract][Full Text] [Related]
25. Discordant response of low-density lipoprotein cholesterol and lipoprotein(a) levels to monoclonal antibodies targeting proprotein convertase subtilisin/kexin type 9.
Edmiston JB; Brooks N; Tavori H; Minnier J; Duell B; Purnell JQ; Kaufman T; Wojcik C; Voros S; Fazio S; Shapiro MD
J Clin Lipidol; 2017; 11(3):667-673. PubMed ID: 28506388
[TBL] [Abstract][Full Text] [Related]
26. Apolipoprotein(a) size and lipoprotein(a) concentration and future risk of angina pectoris with evidence of severe coronary atherosclerosis in men: The Physicians' Health Study.
Rifai N; Ma J; Sacks FM; Ridker PM; Hernandez WJ; Stampfer MJ; Marcovina SM
Clin Chem; 2004 Aug; 50(8):1364-71. PubMed ID: 15155542
[TBL] [Abstract][Full Text] [Related]
27. Mipomersen, an apolipoprotein B synthesis inhibitor, reduces atherogenic lipoproteins in patients with severe hypercholesterolemia at high cardiovascular risk: a randomized, double-blind, placebo-controlled trial.
Thomas GS; Cromwell WC; Ali S; Chin W; Flaim JD; Davidson M
J Am Coll Cardiol; 2013 Dec; 62(23):2178-84. PubMed ID: 24013058
[TBL] [Abstract][Full Text] [Related]
28. Antisense oligonucleotide directed to human apolipoprotein B-100 reduces lipoprotein(a) levels and oxidized phospholipids on human apolipoprotein B-100 particles in lipoprotein(a) transgenic mice.
Merki E; Graham MJ; Mullick AE; Miller ER; Crooke RM; Pitas RE; Witztum JL; Tsimikas S
Circulation; 2008 Aug; 118(7):743-53. PubMed ID: 18663084
[TBL] [Abstract][Full Text] [Related]
29. High lipoprotein(a) levels and small apolipoprotein(a) size prospectively predict cardiovascular events in dialysis patients.
Longenecker JC; Klag MJ; Marcovina SM; Liu YM; Jaar BG; Powe NR; Fink NE; Levey AS; Coresh J
J Am Soc Nephrol; 2005 Jun; 16(6):1794-802. PubMed ID: 15800123
[TBL] [Abstract][Full Text] [Related]
30. Variation in lipoprotein(a) concentrations among individuals with the same apolipoprotein (a) isoform is determined by the rate of lipoprotein(a) production.
Rader DJ; Cain W; Zech LA; Usher D; Brewer HB
J Clin Invest; 1993 Feb; 91(2):443-7. PubMed ID: 8432853
[TBL] [Abstract][Full Text] [Related]
31. Effects of lowering elevated LDL cholesterol on the cardiovascular risk of lipoprotein(a).
Maher VM; Brown BG; Marcovina SM; Hillger LA; Zhao XQ; Albers JJ
JAMA; 1995 Dec; 274(22):1771-4. PubMed ID: 7500507
[TBL] [Abstract][Full Text] [Related]
32. Elevated plasma lipoprotein(a) in patients with the nephrotic syndrome.
Wanner C; Rader D; Bartens W; Krämer J; Brewer HB; Schollmeyer P; Wieland H
Ann Intern Med; 1993 Aug; 119(4):263-9. PubMed ID: 8328733
[TBL] [Abstract][Full Text] [Related]
33. Lipoprotein(a) level and apolipoprotein(a) phenotype as predictors of long-term cardiovascular outcomes after coronary artery bypass grafting.
Ezhov MV; Safarova MS; Afanasieva OI; Kukharchuk VV; Pokrovsky SN
Atherosclerosis; 2014 Aug; 235(2):477-82. PubMed ID: 24952151
[TBL] [Abstract][Full Text] [Related]
34. Levels of lipoprotein and homocysteine in non-obese and obese patients with polycystic ovary syndrome.
Yilmaz M; Biri A; Bukan N; Karakoç A; Sancak B; Törüner F; Paşaoğlu H
Gynecol Endocrinol; 2005 May; 20(5):258-63. PubMed ID: 16019370
[TBL] [Abstract][Full Text] [Related]
35. Lipoprotein(a)-apheresis in the light of new drug developments.
Vogt A
Atheroscler Suppl; 2017 Nov; 30():38-43. PubMed ID: 29096859
[TBL] [Abstract][Full Text] [Related]
36. Effects of mipomersen, an apolipoprotein B100 antisense, on lipoprotein (a) metabolism in healthy subjects.
Nandakumar R; Matveyenko A; Thomas T; Pavlyha M; Ngai C; Holleran S; Ramakrishnan R; Ginsberg HN; Karmally W; Marcovina SM; Reyes-Soffer G
J Lipid Res; 2018 Dec; 59(12):2397-2402. PubMed ID: 30293969
[TBL] [Abstract][Full Text] [Related]
37. Antisense inhibition of apolipoprotein (a) to lower plasma lipoprotein (a) levels in humans.
Graham MJ; Viney N; Crooke RM; Tsimikas S
J Lipid Res; 2016 Mar; 57(3):340-51. PubMed ID: 26538546
[TBL] [Abstract][Full Text] [Related]
38. Lipoprotein(a)- and low-density lipoprotein-derived cholesterol in nephrotic syndrome: Impact on lipid-lowering therapy?
Kronenberg F; Lingenhel A; Lhotta K; Rantner B; Kronenberg MF; König P; Thiery J; Koch M; von Eckardstein A; Dieplinger H
Kidney Int; 2004 Jul; 66(1):348-54. PubMed ID: 15200443
[TBL] [Abstract][Full Text] [Related]
39. Effect of Pelacarsen on Lipoprotein(a) Cholesterol and Corrected Low-Density Lipoprotein Cholesterol.
Yeang C; Karwatowska-Prokopczuk E; Su F; Dinh B; Xia S; Witztum JL; Tsimikas S
J Am Coll Cardiol; 2022 Mar; 79(11):1035-1046. PubMed ID: 35300814
[TBL] [Abstract][Full Text] [Related]
40. Different apoprotein(a) isoform proportions in serum and carotid plaque.
Baldo G; Giunco S; Kontothanassis D; Baiocchi MR; Valerio A; Frego M
Atherosclerosis; 2007 Jul; 193(1):177-85. PubMed ID: 16839560
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
